As GLP1 drugs get approval for Type 2 Diabetes treatment in India, Tony and Nitin get deep into Ozempic and its likes, debating the moral, ethical and commercial questions around them, and other cosmetic procedures. Stay on for the last third of this discussion, where they imagine the challenges of keeping the spark alive in a world full of dopamine, that also features shortcuts that can destroy the joy of experience involved in food, exercise and creativity.